The stock of BioScrip Inc (NASDAQ:BIOS) hit a new 52-week high and has $7.22 target or 140.00% above today’s $3.01 share price. The 9 months bullish chart indicates low risk for the $342.78M company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $7.22 price target is reached, the company will be worth $479.89M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 697,208 shares traded hands or 39.81% up from the average. BioScrip Inc (NASDAQ:BIOS) has risen 33.80% since February 29, 2016 and is uptrending. It has outperformed by 21.58% the S&P500.
Analysts await BioScrip Inc (NASDAQ:BIOS) to report earnings on November, 2. They expect $-0.06 EPS, up 68.42% or $0.13 from last year’s $-0.19 per share. After $-0.08 actual EPS reported by BioScrip Inc for the previous quarter, Wall Street now forecasts -25.00% EPS growth.
BioScrip Inc (NASDAQ:BIOS) Ratings Coverage
Out of 2 analysts covering BioScrip (NASDAQ:BIOS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioScrip has been the topic of 2 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Dougherty & Company on Wednesday, August 12 with “Buy”. The stock has “Buy” rating given by SunTrust on Tuesday, August 11.
According to Zacks Investment Research, “BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.”
Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.36, from 1.15 in 2016Q1. The ratio is positive, as 13 funds sold all BioScrip Inc shares owned while 26 reduced positions. 24 funds bought stakes while 35 increased positions. They now own 92.45 million shares or 63.22% more from 56.64 million shares in 2016Q1.
Alyeska Investment L P has 0.03% invested in the company for 1.30 million shares. Tiaa Cref Investment Ltd last reported 0% of its portfolio in the stock. Blackrock Invest Ltd Liability Com owns 280,671 shares or 0% of their US portfolio. Oppenheimer And Communication last reported 0% of its portfolio in the stock. Credit Suisse Ag reported 57,378 shares or 0% of all its holdings. Moreover, Legal And General Group Plc has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 12,461 shares. Blackstone Grp Lp holds 16,802 shares or 0% of its portfolio. Diamond Hill Cap Management has 0.09% invested in the company for 5.32M shares. Teton, a New York-based fund reported 1.14 million shares. Eidelman Virant Cap accumulated 42,000 shares or 0.66% of the stock. Blackrock last reported 0% of its portfolio in the stock. Pnc Financial Ser Group last reported 74,362 shares in the company. Coliseum Cap Mngmt Ltd Liability Corporation owns 5.62 million shares or 5.98% of their US portfolio. Bridgeway Mngmt last reported 0.01% of its portfolio in the stock. Marathon Capital, a Maryland-based fund reported 291,750 shares.
More recent BioScrip Inc (NASDAQ:BIOS) news were published by: Fool.com which released: “Why Shares of BioScrip, Inc. Are Crashing Today” on May 08, 2015. Also Moodys.com published the news titled: “Moody’s downgrades BioScrip’s CFR to Caa2; outlook stable” on March 03, 2016. Globenewswire.com‘s news article titled: “BioScrip Announces Transformative Acquisition of Home Solutions That Will …” with publication date: June 13, 2016 was also an interesting one.
BIOS Company Profile
BioScrip, Inc., incorporated on March 22, 1996, is engaged in providing infusion solutions. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Firm operates through Infusion Services segment. The Firm operates through approximately 70 service locations in over 30 states. The Firm offers home infusion services to provide clinical management services and the delivery of prescription medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.